期刊
CANCER LETTERS
卷 278, 期 2, 页码 145-155出版社
ELSEVIER IRELAND LTD
DOI: 10.1016/j.canlet.2008.12.031
关键词
NF-kappa B; Hepatocellular carcinoma (HCC); Sorafenib; Therapy
类别
资金
- National Cancer Institute [K22-CA111393]
Nuclear factor-kappaB (NF-kappa B) has been shown to play an important role in the development and progression of cancer. In this study, we systematically examined NF-kappa Bp65 signaling pathway in both human hepatocellular carcinoma (HCC) tissue and HCC cell lines. NF-kappa Bp65 signaling pathway is aberrantly expressed and activated in both human HCC tissue and HCC Hep3B cells. Inhibition of NF-kappa B activity significantly reduced proliferation and invasion of Hep3B cells as well as down-regulated the expression of invasion-related molecules including matrix metalloproteinase (MMP)-2, MMP-9, membrane type-1 MMP (MT1-MMP), urokinase plasminogen activator (uPA) and vascular endothelial growth factor (VEGF). Hep3B cells exhibited a dose-dependent increase in apoptosis after receiving sorafenib treatment. Inhibition of NF-kappa B activity strongly sensitized Hep3B cells to sorafenib-induced cell death. Mechanistically, combined treatment of sorafenib and NF-kappa B inhibition enhanced inhibition of MAPK signaling and down-regulation of anti-apoptotic protein Mcl-1 expression. These observations indicate that inhibition of NF-kappa B may be a potential antineoplastic therapy for HCC, especially the combination of NF-kappa B inhibition and sorafenib provides a novel therapeutic strategy for patients with advanced-stage HCC. (C) 2009 Published by Elsevier Ireland Ltd.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据